Date:8/13/2009

2009 2008 -------- ------------ (Unaudited) (Audited) Current assets: Cash and cash equivalents $21,008,261 $19,236,212 Short term investments 3,135,321 5,048,775 Interest receivable 7,151 13,116 Prepaid and other current assets 40,140 14,090 ----------- ----------- Total current assets 24,190,873 24,312,193 Investment in other ventures 194,046 193,718 Patents, net 421,184 464,401 ----------- ----------- Total assets $24,806,103 $24,970,312 =========== =========== LIABILITIES AND STOCKHOLDERS' EQUITY ------------------------------------ Current liabilities: Accrued expenses and other current liabilities $26,748 $15,055 ----------- ----------- Total current liabilities 26,748 15,055 ----------- ----------- Commitments Stockholders' equity: Common stock 132,857 132,857 Additional paid-in capital 59,847,443 59,847,443 Accumulated deficit (34,900,870) (34,724,968) Treasury stock - at cost (300,075) (300,075) ----------- ---------
'/>"/>

SOURCE Cadus Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5
Related biology technology :

1. Cadus Reports Second Quarter 2008 Results
2. Cadus Reports First Quarter 2008 Results
3. Cadus Reports Second Quarter 2007 Results
4. Cadus Reports Third Quarter 2007 Results
5. PharmAthene Reports Second Quarter 2009 Financial and Operational Results
6. Amsterdam Molecular Therapeutics Reports Half Year Results 2009
7. Transgenomic, Inc. Reports Second Quarter 2009 Results
8. BioSpecifics Technologies Corp. Reports Second Quarter 2009 Financial Results
9. Oncothyreon reports second quarter 2009 financial results
10. ADVENTRX Pharmaceuticals Reports Second Quarter Financial Results
11. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration